Cingulate Inc. Form 8-K Summary
Business Context and Reporting Period
Cingulate Inc. (CING), a Delaware corporation, filed this Current Report on Form 8-K on October 14, 2025. The Company is an emerging growth company focused on developing treatments for attention deficit/hyperactivity disorder (ADHD). Its principal executive offices are located in Kansas City, KS.
Key Financial Metrics
This filing is a regulatory disclosure regarding a corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corporate Events
- Regulatory Milestone: The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CTx-1301 (dexmethylphenidate).
- Product Focus: CTx-1301 is the Company's lead candidate for the treatment of ADHD in both children and adults.
- Timeline: The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026.
Outlook, Risks, and Management Commentary
Management, represented by Interim CEO and CFO Jennifer L. Callahan, highlighted the NDA acceptance as a significant step toward potential market approval. The primary contingency is the FDA's review process, with a definitive decision expected by the PDUFA date of May 31, 2026. No specific financial guidance or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the PDUFA target action date of May 31, 2026, for the CTx-1301 NDA.
- Review the attached press release (Exhibit 99.1) for detailed clinical data supporting the NDA.
- Monitor subsequent filings for any FDA Complete Response Letters or approval decisions.
- Check the Company's cash runway in upcoming quarterly reports (10-Q/10-K) given the lack of revenue data in this filing.